Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

34.52

Mkt cap

2B

Volume

220K

High

35.37

P/E Ratio

16.50

52-wk high

41.61

Low

34.28

Div yield

N/A

52-wk low

22.89

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 10:57 am

Analysts have mixed views on Harmony Biosciences (NASDAQ:HRMY) with 4 analysts rating it bullish over the past three months. The average 12-month price target is $51.0, slightly down from $52.0. The company shows strong financial performance with significant revenue growth, high net margin, and effective debt management.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 8:01 pm

Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 6:09 pm

Harmony Biosciences announced that it is on track to submit a supplemental new drug application (sNDA) for Pitolisant in the treatment of idiopathic hypersomnia by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:58 am

Harmony Biosciences has reiterated its 2024 net product revenue guidance of $700M - $720M, aligning with the estimated $710.288M. The company reported cash, cash equivalents, and investments of $434.1 million as of June 30, 2024, up from $425.6 million as of December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:57 am

Harmony Biosciences (NASDAQ:HRMY) reported Q2 2024 adjusted EPS of $1.05, significantly beating the $(0.06) estimate, and a 38.16% increase from last year. However, sales of $172.814M slightly missed the $173.098M estimate, though they were up 28.76% from the previous year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:46 am

The FDA has confirmed a favorable benefit-risk profile for WAKIX, a drug by Harmony Biosciences. The company plans to launch at least one new product or indication annually over the next five years. The denial of a citizen petition further confirms WAKIX's safety and efficacy for treating EDS and cataplexy in adults with narcolepsy.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 12:07 pm

Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 9:30 am

Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $52 price target.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 5:01 pm

Harmony Biosciences has received FDA approval for a supplemental new drug application for WAKIX, which is expected to enhance its market position and potentially increase revenues.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.